![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alizyme | LSE:AZM | London | Ordinary Share | GB0000374289 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.08 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAZM RNS Number : 2750W Alizyme PLC 24 July 2009 +---------------------------------------+---------------------------------------+ | FOR IMMEDIATE RELEASE | 24 JULY 2009 | +---------------------------------------+---------------------------------------+ ALIZYME PLC SUSPENSION OF SHARES FOR TRADING ON THE OFFICIAL LIST, COMPANY TO BE PLACED INTO ADMINISTRATION Alizyme plc (LSE: AZM) ("Alizyme" or the "Company") Cambridge UK, 24 July 2009: Alizyme PLC announces that, at its own request, trading in the Company's ordinary shares has been suspended with effect from 3.30 pm on 24 July 2009, following which the Board has agreed to appoint Ian Carr and Nigel Morrison of Grant Thornton UK LLP to act as Administrators of the Company. On 29 June 2009, the Company announced in a trading update that it did not expect to have sufficient funding to last beyond the end of August 2009 and that it would be unable to continue as a going concern without urgently raising additional funds. As part of the trading update, the Company also announced that it was in discussions with its commercial partners to mitigate potential increased funding obligations under its licensing and development agreements with regard to COLAL-PRED . The Company was today notified by Prometheus Laboratories Inc ("Prometheus") that a complaint had been filed with the United States District Court, Southern District of California, regarding an alleged breach of a Licence Agreement between Prometheus and Alizyme Therapeutics Limited, a wholly owned subsidiary of Alizyme. The complaint was filed on 21 July 2009, but has not been served on Alizyme Therapeutics Limited or Alizyme. The Company no longer believes that it will be able to conclude successfully the discussions with its commercial partners, and therefore does not believe that refinancing of the Company could now be completed, within a timeframe during which the Company would have sufficient cash reserves to continue trading. As a result, the Board of Alizyme has taken advice and with great regret no longer believes that the Company is in a position to continue its operations. It is expected that the appointment of Administrators will take place either today or on Monday 27 July 2009, following which the Administrators will take such measures as they believe appropriate, including seeking a buyer for the Company and/or its assets. The Board of Directors of Alizyme Therapeutics Limited ("ATL") has also agreed to appoint the above named persons from Grant Thornton UK LLP to act as administrators of ATL. In addition, the Annual General Meeting, which had been convened for 12.00 pm on Wednesday, 29 July 2009, will no longer take place. For further information please call: Ian Carr Grant Thornton UK LLP Byron House Cambridge Business Park Cambridge CB4 0WZ Telephone: +44 (0) 1223 225600 Email: ian.carr@gtuk.com Press Enquiries: Cathy Connan PR and Communication Connan Limited Telephone: +44 (0) 7976 669089 Email: cathy@cathyconnan.com This information is provided by RNS The company news service from the London Stock Exchange END SRSUSSSRKSRBUAR
1 Year Alizyme Chart |
1 Month Alizyme Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions